Our results also suggested that a CDK inhibitor would be useful in the treatment of ESCC by enhancing the sensitivity to chemotherapy especially in patients with PFTK1(+) tumours, in support of previous reports (Schwartz et al, 2002). This evidence concerns the gene CDK14 and esophageal squamous cell carcinoma.